{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:36Z","timestamp":1791155376687,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Four patients with the acquired immunodeficiency syndrome and Kaposi\u2019s sarcoma were treated with subcutaneous human recombinant \u03b3-interferon at a dosage of 200 \u03bcg 2 \u00d7 106U twice daily for at least 28 days. While the dosage of interferon was well tolerated, progressive disease was observed in all four patients studied. These results might be due to the selection of the patients presenting advanced stages (3 out of 4) with recurrent disease after previous chemotherapy.<\/jats:p>","DOI":"10.1159\/000215998","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T09:41:27Z","timestamp":1240566087000},"page":"163-166","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of AIDS-Related Kaposi\u2019s Sarcoma with Recombinant \u03b3-Interferon"],"prefix":"10.1159","author":[{"given":"A.","family":"Ganser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Br\u00fccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Brodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Brandhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.B.","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,4,24]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000215998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:59:34Z","timestamp":1777679974000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000215998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000215998","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,24]]}}}